Maria Assunta Silvestri Selected Research

pembrolizumab

10/2023	Immune-related adverse events and disease outcomes after the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients receiving immune checkpoint inhibitors.
7/2023	Changes in Peripheral Immune Cells after the Third Dose of SARS-CoV-2 mRNA-BNT162b2 Vaccine and Disease Outcomes in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Prospective Analysis of the Vax-on-Third-Profile Study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Maria Assunta Silvestri Research Topics

Disease

5	Neoplasms (Cancer) 01/2024 - 12/2022
4	COVID-19 01/2024 - 12/2022
2	Lung Neoplasms (Lung Cancer) 10/2023 - 07/2023
1	Herpes Zoster 01/2024
1	Breast Neoplasms (Breast Cancer) 01/2023
1	Breakthrough Infections 01/2023
1	Infections 12/2022
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 09/2022

Drug/Important Bio-Agent (IBA)

6	VaccinesIBA 01/2024 - 12/2022
3	BNT162 VaccineIBA 01/2024 - 01/2023
3	Immune Checkpoint InhibitorsIBA 10/2023 - 09/2022
2	pembrolizumabIBA 10/2023 - 07/2023
2	NivolumabIBA 10/2023 - 07/2023
1	Messenger RNA (mRNA)IBA 01/2024
1	mRNA VaccinesIBA 07/2023
1	Immunoglobulin G (IgG)IBA 12/2022

Therapy/Procedure

2	Time-to-Treatment 01/2023 - 01/2023
2	Therapeutics 01/2023 - 09/2022